Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.31 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.31 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248680 | 0.74 | GAA (0.33) | GAACRHBPCRHR2 | |
| SCHEMBL436830 | 0.74 | GAA (0.33) | GAACRHBPCRHR2 | |
| SCHEMBL11331048 | 0.73 | APEX1 (0.50) | APEX1GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL6050582 | 0.73 | APEX1 (0.50) | APEX1GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL27570798 | 0.72 | — | — | |
| SCHEMBL14958921 | 0.70 | GAA (0.32) | GAA | |
| SCHEMBL2348600 | 0.68 | GAA (0.30) | GAA | |
| SCHEMBL9452647 | 0.67 | — | — | |
| SCHEMBL13592844 | 0.66 | GAA (0.30) | GAA | |
| SCHEMBL7765575 | 0.65 | KCNA4 (0.34) | APEX1GAAALDH1A1KCNA4KCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291935-A1 | X-NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | RADIORX, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291935-A1 | X-NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | XDH, TXN, NOX1 | APEX1 285/4885GAA 1050/4885CRHBP 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.